RxDoctor Payments Data

Aakash Aggarwal, MD

Gastroenterology · Hackensack, NJNPI 1942597588

Payments from drug & device makers

$5,936in general payments, 2019–2025

Across 268 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$888
  • Covidien LP$885
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$622
  • Johnson & Johnson$476
  • Regeneron Healthcare Solutions, Inc.$463
  • Takeda Pharmaceuticals U.S.A., Inc.$339
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$71312%
  • Food & beverage$5,18187%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,936 in reported general payments places this provider in the 70th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$169,991
Medicare patients
445
Services billed
1,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide64$36,783
XifaxanRifaximin11$26,469
TrulancePlecanatide26$17,541
Sucralfate30$7,808
Omeprazole293$4,514
Famotidine213$3,028
ClenpiqSod Picosulf/Mag Ox/Citric Ac17$2,959
Lubiprostone18$2,368
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl85$1,294
Lactulose14$1,134
Dicyclomine Hcl62$1,111
Pantoprazole Sodium71$646
Ursodiol16$635
Esomeprazole Magnesium18$364
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$622$44,00937 claims
AbbVieLinzess$888$36,78364 claims
Ferring Pharmaceuticals Inc.Clenpiq$54$2,95917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →